SIRION Expedites AAV Production with Increased Lab Capacity

SIRION Biotech, a global supplier of high-quality AAV vectors, has expanded its staff to meet the growing market demand for high scale AAV products in the preclinical sector.

The number of gene therapy clinical trials is increasing every year, as is the number of researchers developing new targets and therapies. This growing market demand, combined with supply challenges due to the pandemic and the war in Ukraine, led to production bottlenecks and delays worldwide. 

"Our additional staff has allowed us to bring our AAV production lead time down to just 2 weeks in our new ISO-Certified facility in Graefelfing." says Dr. Kathrin Schneider, SVP Global Business. " This will help our customers to run their experiments and generate critical data to meet their timelines."

About SIRION Biotech

SIRION Biotech was founded in 2005 with the goal to spark a new generation of viral vector technologies for gene and cell therapy as well as vaccine development. SIRION evolves novel therapeutic viral vectors and uses proprietary technology platforms based on lenti-, adeno-, and adeno-associated viruses, to expedite its partners’ advances in drug development. On August 31, 2021, SIRION was taken over entirely by Revvity. For additional information, please visit www.sirion-biotech.com.